Building Breakthroughs

On the Frontier of Medical Innovation

Raju Prasad (Equity Research Analyst, William Blair and Company, L.L.C.)

$61.99

Hardback

Not in-store but you can order this
How long will it take?

Availability Information

We source books from suppliers in Australia and overseas. For books we don't currently have in stock, the time it takes to get them from our suppliers can vary widely - from a few days to a few months - so we check each book with each supplier to determine the expected time it will take to be supplied to us.

We then advise you accordingly. If the time taken to get any book is too long for you, you can let us know and we will cancel or adjust your order, and refund as required.

To find out the anticipated arrival time for specific items prior to ordering, please contact us by phone or email:

Phone +61 2 9264 3111, or 1800 4 BOOKS (1800 4 26657) if outside Sydney:
option 1 Abbey's Bookshop (Crime, History, Science, Kids & more) • info@abbeys.com.au
option 2 Language Book Centre (ESL & Foreign Languages) • language@abbeys.com.au
option 3 Galaxy Bookshop (Sci-fi, Fantasy, Romance, Graphic Novels) • sf@galaxybooks.com.au

QTY:

English

Johns Hopkins University Press
06 December 2022

Public health & preventive medicine

From mRNA vaccines to gene therapies, the next frontier of medical innovation is here.

In Building Breakthroughs, Raju Prasad tells the story of important advancements in biotechnology and medical innovation from gene therapies to mRNA vaccines, providing historical context and examining cutting-edge research. Based on in-depth interviews with both the scientists who developed these discoveries and the patients who have benefited from them, Building Breakthroughs reveals the key players behind drug development and the inner workings of this essential business.

Through stories of patients and their families, and of the researchers creating new treatments, Prasad reveals how cell therapies are advancing to treat childhood leukemia and a form of lymphoma, how a gene therapy was established to treat the rare disease spinal muscular atrophy type I, and potentially curative therapies that are being developed for sickle cell disease. By examining the clinical trial and regulatory paths each therapy took to reach approval, Prasad uncovers the building blocks of biotechnology innovation and the investments that must be made to catalyze the development of future breakthroughs. He also explores issues of scientific communication and misinformation, providing recommendations for improvements in the future.

For those seeking to understand the vitally important processes that lead to new medicines and the surrounding ecosystem that is enabling the next generation of innovative medicines with the potential to transform patient outcomes, Building Breakthroughs is essential reading.

By: Raju Prasad (Equity Research Analyst William Blair and Company L.L.C.)
Imprint: Johns Hopkins University Press
Country of Publication: United States
Dimensions: Height: 229mm, Width: 152mm, Spine: 22mm
Weight: 454g
ISBN: 9781421444871
ISBN 10: 1421444879
Pages: 240
Publication Date: 06 December 2022
Audience: General/trade , ELT Advanced
Format: Hardback
Publisher's Status: Active

Introduction Part I. The Journey from Idea to Approval Chapter 1. Leukemia and Lymphoma Chapter 2. Chimeric Antigen Receptor (CAR)-T Cell Therapy Chapter 3. Spinal Muscular Atrophy Chapter 4. In Vivo Gene Therapy Chapter 5. Sickle Cell Anemia Chapter 6. Ex Vivo Gene-Modified Cell Therapy Chapter 7. A Brief History of FDA Regulation Chapter 8. The Path to Approval Part II. Enabling the Next Wave Of Innovation Chapter 9. Building Blocks Chapter 10. Recognizing Value Chapter 11. Financial and Human Capital Investments in Biotechnology Chapter 12. Looking Forward Epilogue. COVID-19 Acknowledgments References Index

Raju Prasad, PhD (CHICAGO, IL), is a partner and biotechnology analyst at William Blair, focusing on cell therapy, gene therapy, and gene editing. Dr. Prasad previously worked as a research associate with the University of North Carolina at Chapel Hill's Gillings School of Global Public Health and as an independent consultant with the US Environmental Protection Agency.